Tryptophan metabolism reprogramming potentially contributes to the prothrombotic milieu in mice and humans with SARS-CoV-2

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection disturbs the coagulation balance in the blood, triggering thrombosis and contributing to organ failure. The role of prothrombotic metabolites in COVID-19-associated coagulopathy remains elusive. Leveraging K18-hACE2 mice infected with SARS-CoV-2, we observed higher levels of the tryptophan metabolite, kynurenine, than in controls. SARS-CoV-2-infected mice showed a significant upregulation of enzymes controlling kynurenine biogenesis, such as indoleamine 2,3-dioxygenase 1 (IDO-1) and tryptophan 2,3-dioxygenase in the kidney and liver, respectively, as well as changes in the enzymes involved in kynurenine catabolism, including kynurenine monooxygenase and kynurinase. Consistent with the agonistic role of these metabolites in aryl hydrocarbon receptor (AHR) signaling, AHR activation and its downstream mediator, tissue factor (TF), a highly potent procoagulant factor, was observed in endothelial cells (ECs) of lungs and kidneys of infected mice. These findings were validated in humans. Compared with controls, sera of patients with COVID-19 showed increased levels of kynurenine, kynurenic acid, anthranilic acid, and quinolinic acid. Activation of the AHR-TF axis was noted in the kidneys and lungs of patients with COVID-19, and sera from patients infected with SARS-CoV-2 showed higher IDO-1 activity than controls. Kynurenine levels in patients with COVID-19 correlated strongly with the TF-inducing activity of sera from patients infected with SARS-CoV-2 on ECs. A specific IDO-1 inhibitor or AHR inhibitor separately or in combination suppressed sera from induced TF activity in ECs from patients with COVID-19. Together, we identified IDO-1 as upregulated by SARS-CoV-2 infection, resulting in augmented kynurenine and its prothrombotic catabolites, thereby suggesting the kynurenine-AHR-TF axis as a potential new diagnostic and therapeutic target.

Authors

Institutions

Publication Details

Journal
Blood Vessels Thrombosis & Hemostasis
Published
2026-01-05
DOI
https://doi.org/10.1016/j.bvth.2025.100128
Primary Topic
COVID-19 Clinical Research Studies
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Tryptophan metabolism reprogramming potentially contributes to the prothrombotic milieu in mice and humans with SARS-CoV-2

Vijaya B. Kolachalama, Eric Burks, Vipul C. Chitalia, Katya Ravid et al.
Blood Vessels Thrombosis & Hemostasis
COVID-19 Clinical Research Studies
article

Tryptophan metabolism reprogramming potentially contributes to the prothrombotic milieu in mice and humans with SARS-CoV-2

Vijaya B. Kolachalama, Eric Burks, Vipul C. Chitalia, Katya Ravid, Murad Elsadawi, Marc A. Napoleon, Florian Douam, Grace Zhao, Devin Kenney, David Jasen Wu Wong, Markus Bosmann, Christina Francis, Helena Kurniawan, Stephen Whelan, Saran Lotfollahzadeh, Howard Cabral, Saravanan Subramaniam, Mohamed Hassan Kamal
article en

Abstract

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection disturbs the coagulation balance in the blood, triggering thrombosis and contributing to organ failure. The role of prothrombotic metabolites in COVID-19-associated coagulopathy remains elusive. Leveraging K18-hACE2 mice infected with SARS-CoV-2, we observed higher levels of the tryptophan metabolite, kynurenine, than in controls. SARS-CoV-2-infected mice showed a significant upregulation of enzymes controlling kynurenine biogenesis, such as indoleamine 2,3-dioxygenase 1 (IDO-1) and tryptophan 2,3-dioxygenase in the kidney and liver, respectively, as well as changes in the enzymes involved in kynurenine catabolism, including kynurenine monooxygenase and kynurinase. Consistent with the agonistic role of these metabolites in aryl hydrocarbon receptor (AHR) signaling, AHR activation and its downstream mediator, tissue factor (TF), a highly potent procoagulant factor, was observed in endothelial cells (ECs) of lungs and kidneys of infected mice. These findings were validated in humans. Compared with controls, sera of patients with COVID-19 showed increased levels of kynurenine, kynurenic acid, anthranilic acid, and quinolinic acid. Activation of the AHR-TF axis was noted in the kidneys and lungs of patients with COVID-19, and sera from patients infected with SARS-CoV-2 showed higher IDO-1 activity than controls. Kynurenine levels in patients with COVID-19 correlated strongly with the TF-inducing activity of sera from patients infected with SARS-CoV-2 on ECs. A specific IDO-1 inhibitor or AHR inhibitor separately or in combination suppressed sera from induced TF activity in ECs from patients with COVID-19. Together, we identified IDO-1 as upregulated by SARS-CoV-2 infection, resulting in augmented kynurenine and its prothrombotic catabolites, thereby suggesting the kynurenine-AHR-TF axis as a potential new diagnostic and therapeutic target.

Blood Vessels Thrombosis & HemostasisVol. 3(1)
Boston University (US), Massachusetts College of Pharmacy and Health Sciences (US), Johannes Gutenberg University Mainz (DE), VA Boston Healthcare System (US), University Medical Center of the Johannes Gutenberg University Mainz (DE)
Zero hunger
Openalex Percentile: Top 98%
COVID-19 Clinical Research Studies
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.